Angelo Di Leo

List of Publications by Year
in descending order

183 papers	15,533 citations	26567 56 h-index	18075 120 g-index
186 all docs	186 docs citations	186 times ranked	18453 citing authors

#	Article	IF	Citations
1	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
2	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 2013, 31, 860-867.	0.8	1,342
3	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3638-3646.	0.8	1,099
4	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	5.1	717
5	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4594-4600.	0.8	553
6	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018, 379, 122-137.	13.9	448
7	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5544-5552.	0.8	407
8	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1879-1887.	0.8	388
9	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer, 2019, 5, 5.	2.3	352
10	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	5.1	342
11	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncology, The, 2019, 20, 371-382.	5.1	327
12	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 87-100.	5.1	307
13	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	2.0	265
14	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	6.3	260
15	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	3.0	218
16	Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications. Journal of Clinical Oncology, 2007, 25, 2840-2846.	0.8	217
17	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	0.8	210
18	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Research and Treatment, 2009, 118, 523-530.	1.1	199

#	Article	IF	Citations
19	HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clinical Cancer Research, 2002, 8, 1107-16.	3.2	195
20	Management of triple negative breast cancer. Breast, 2010, 19, 312-321.	0.9	171
21	Multifactorial Approach to Predicting Resistance to Anthracyclines. Journal of Clinical Oncology, 2011, 29, 1578-1586.	0.8	169
22	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncology, The, 2011, 12, 1134-1142.	5.1	165
23	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 7861-7870.	3.2	159
24	Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2001, 19, 3103-3110.	0.8	157
25	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3908-3915.	0.8	154
26	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Molecular Oncology, 2015, 9, 749-757.	2.1	146
27	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Journal of Clinical Oncology, 2015, 33, 1574-1583.	0.8	146
28	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. Oncologist, 2015, 20, 474-482.	1.9	145
29	The nutritional risk in oncology: a study of 1,453 cancer outpatients. Supportive Care in Cancer, 2012, 20, 1919-1928.	1.0	142
30	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. Journal of the National Cancer Institute, 2008, 100, 121-133.	3.0	140
31	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Research and Treatment, 2010, 119, 145-153.	1.1	137
32	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget, 2016, 7, 26107-26119.	0.8	136
33	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 541-552.	12.5	121
34	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666.	1.3	113
35	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget, 2016, 7, 68012-68022.	0.8	110
36	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106

#	Article	IF	Citations
37	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	3.4	106
38	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Research and Treatment, 2012, 134, 283-289.	1.1	101
39	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 22-36.	12.5	97
40	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	5.1	91
41	Metabolomics in breast cancer: A decade in review. Cancer Treatment Reviews, 2018, 67, 88-96.	3.4	87
42	Breast cancer assessment tools and optimizing adjuvant therapy. Nature Reviews Clinical Oncology, 2010, 7, 725-732.	12.5	83
43	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Molecular Oncology, 2015, 9, 128-139.	2.1	82
44	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
45	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	2.3	78
46	Uncovering the metabolomic fingerprint of breast cancer. International Journal of Biochemistry and Cell Biology, 2011, 43, 1010-1020.	1.2	77
47	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76
48	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist, 2013, 18, 1063-1073.	1.9	75
49	Metabolomics in cancer: A bench-to-bedside intersection. Critical Reviews in Oncology/Hematology, 2012, 84, 1-7.	2.0	74
50	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. Molecular Oncology, 2012, 6, 437-444.	2.1	73
51	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Molecular Cancer Therapeutics, 2006, 5, 2572-2579.	1.9	72
52	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology, 2019, 37, 105-114.	0.8	72
53	Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer. Journal of Clinical Oncology, 2003, 21, 2045-2047.	0.8	69
54	Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Research, 2009, 11, 205.	2.2	66

#	Article	IF	Citations
55	HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact. Cancer Treatment Reviews, 2013, 39, 947-957.	3.4	66
56	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. Clinical Cancer Research, 2017, 23, 1422-1431.	3.2	65
57	*TP53* mutation–correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in *TP53*–mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	2.1	59
58	Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research, 2008, 14, 4511-4516.	3.2	58
59	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3–98. Psycho-Oncology, 2014, 23, 173-182.	1.0	55
60	Predicting Anthracycline Benefit: *TOP2A* and CEP17—Not Only but Also. Journal of Clinical Oncology, 2015, 33, 1680-1687.	0.8	55
61	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308.	0.8	53
62	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. Cancers, 2019, 11, 1894.	1.7	53
63	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial;) Tj ETQq1 1 0.784314 rgBT /Overl	1.7	52
64	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research, 2012, 14, R70.	2.2	52
65	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	0.8	52
66	Continued value of adjuvant anthracyclines as treatment for early breast cancer. Lancet Oncology, The, 2015, 16, e362-e369.	5.1	50
67	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 101, 316-324.	0.4	50
68	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). European Journal of Cancer, 2007, 43, 725-735.	1.3	49
69	Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study. Journal of Clinical Oncology, 2009, 27, 5552-5558.	0.8	49
70	Current Status of HER2 Testing. Oncology, 2002, 63, 25-32.	0.9	48
71	International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Research, 2014, 16, R43.	2.2	43
72	New approaches for improving outcomes in breast cancer in Europe. Breast, 2015, 24, 321-330.	0.9	42

#	Article	IF	Citations
73	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Npj Breast Cancer, 2018, 4, 41.	2.3	41
74	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139.	3.2	40
75	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	0.8	40
76	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. Journal of Clinical Oncology, 2012, 30, LBA671-LBA671.	0.8	36
77	Using specific cytotoxics with a targeted mind. Breast, 2007, 16, 120-126.	0.9	35
78	Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime?. European Journal of Cancer, 2008, 44, 2791-2798.	1.3	35
79	Recurrence dynamics of breast cancer according to baseline body mass index. European Journal of Cancer, 2017, 87, 10-20.	1.3	35
80	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics Journal, 2019, 19, 556-563.	0.9	35
81	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Current Opinion in Oncology, 2014, 26, 568-575.	1.1	33
82	Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer. Clinical Cancer Research, 2010, 16, 1281-1288.	3.2	32
83	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. PLoS ONE, 2013, 8, e62543.	1.1	32
84	Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer, 2015, 51, 1481-1489.	1.3	32
85	The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treatment Reviews, 2009, 35, 662-667.	3.4	30
86	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer, 2019, 114, 55-66.	1.3	30
87	Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. International Journal for Quality in Health Care, 2012, 24, 411-418.	0.9	28
88	Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?. Cancers, 2014, 6, 684-707.	1.7	28
89	Metabolomics in Breast Cancer: Current Status and Perspectives. Advances in Experimental Medicine and Biology, 2016, 882, 217-234.	0.8	28
90	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Medicine, 2015, 13, 46.	2.3	27

#	ARTICLE	IF	CITATIONS
91	Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. European Journal of Cancer, 2007, 43, 2270-2278.	1.3	26
92	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 922-928.	1.7	26
93	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136.	3.4	25
94	Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. Journal of Clinical Oncology, 2009, 27, 720-725.	0.8	23
95	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews, 2019, 74, 29-34.	3.4	23
96	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2â^' advanced breast cancer. Cancer Treatment Reviews, 2015, 41, 94-104.	3.4	22
97	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. BMC Genomics, 2018, 19, 960.	1.2	22
98	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptorâ€"Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5755-5764.	3.2	20
99	Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin. Journal of Clinical Oncology, 2002, 20, 1145-1146.	0.8	19
100	Chemotherapy for metastatic breast cancer. Current Opinion in Obstetrics and Gynecology, 2004, 16, 37-41.	0.9	19
101	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research, 2019, 21, 71.	2.2	19
102	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Research and Treatment, 2020, 181, 347-359.	1.1	19
103	Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream. Journal of Clinical Oncology, 2008, 26, 5011-5013.	0.8	18
104	Taxanes in the elderly: Can we gain as much and be less toxic?. Critical Reviews in Oncology/Hematology, 2009, 70, 262-271.	2.0	18
105	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 299.	0.6	17
106	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. Breast, 2015, 24, S136-S142.	0.9	17
107	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 936-944.	0.8	17
108	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 329-341.	1.1	17

#	Article	IF	Citations
109	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	1.7	17
110	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiotherapy and Oncology, 2009, 90, 116-121.	0.3	16
111	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 2013, 138, 149-155.	1.1	16
112	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2019, 37, 386-395.	0.8	16
113	Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. Npj Breast Cancer, 2021, 7, 11.	2.3	16
114	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. Critical Reviews in Oncology/Hematology, 2016, 100, 57-68.	2.0	15
115	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. Journal of Clinical Oncology, 2018, 36, 503-503.	0.8	15
116	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori, 2011, 97, 690-2.	0.6	15
117	Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast, 2011, 20, S135-S141.	0.9	14
118	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	1.4	14
119	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers, 2021, 13, 2762.	1.7	14
120	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2â˜) metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	0.8	14
121	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion, 2010, 26, 767-775.	0.9	13
122	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast, 2012, 21, 336-342.	0.9	12
123	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA Journal, 2015, 6, 17.	3.3	12
124	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. Npj Breast Cancer, 2019, 5, 26.	2.3	12
125	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	1.1	12
126	Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. European Journal of Cancer, 2011, 47, S370-S372.	1.3	11

#	Article	IF	Citations
127	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncology, 2013, 9, 1477-1487.	1.1	11
128	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast, 2014, 23, 473-481.	0.9	11
129	Gastric Cancer Metastatic to the Pituitary Gland: A Case Report. Tumori, 2007, 93, 217-219.	0.6	10
130	Polyendocrine Treatment in Estrogen Receptor–Positive Breast Cancer: A "FACT" Yet to Be Proven. Journal of Clinical Oncology, 2012, 30, 1897-1900.	0.8	10
131	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast, 2018, 38, 144-149.	0.9	10
132	Predicting anthracycline benefit: have we made any progress?. Current Opinion in Oncology, 2009, 21, 507-515.	1.1	9
133	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. International Journal of Oncology, 2018, 52, 424-432.	1.4	9
134	Re-searching anthracycline therapy. Breast Cancer Research and Treatment, 2010, 123, 171-175.	1.1	8
135	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. Cancers, 2021, 13, 2640.	1.7	8
136	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Cancer Treatment Reviews, 2002, 28, 275-290.	3.4	6
137	Equivalence Between Ovarian Suppression and Chemotherapy in the Adjuvant Treatment of Endocrine-Responsive Breast Cancer. Journal of Clinical Oncology, 2002, 20, 1954-1955.	0.8	6
138	Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?. Breast, 2009, 18, S18-S24.	0.9	6
139	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. Breast, 2017, 34, S13-S18.	0.9	6
140	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. BMC Cancer, 2018, 18, 932.	1.1	6
141	Targeting Metabolomics in Breast Cancer. Current Breast Cancer Reports, 2012, 4, 249-256.	0.5	5
142	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 3-8.	1.8	5
143	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Research and Treatment, 2018, 170, 351-360.	1.1	5
144	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	5

#	Article	IF	Citations
145	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Research, 2018, 38, 4839-4845.	0.5	5
146	A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 2019, 26, 703-711.	1.3	5
147	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 2019, 120, 959-967.	2.9	5
148	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
149	Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2009, 101, 1735-1736.	3.0	4
150	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. Future Oncology, 2011, 7, 173-186.	1.1	4
151	Using CTCs for pharmacogenomic analysis. Pharmacological Research, 2016, 106, 92-100.	3.1	4
152	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti–HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	2.3	4
153	A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. Npj Breast Cancer, 2015, 1, 15003.	2.3	3
154	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	1.4	3
155	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3. , 2018, , .		3
156	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. Critical Reviews in Oncology/Hematology, 2007, 62, 1-8.	2.0	2
157	RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2017, 109, 1.	3.0	2
158	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1048-1048.	0.8	2
159	Predictive molecular markers of anthracycline effectiveness in early breast cancer. European Journal of Cancer, Supplement, 2011, 9, 16-21.	2.2	1
160	The continued evidence from overviews: What is the clinical utility?. Breast, 2013, 22, S8-S11.	0.9	1
161	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. Breast, 2019, 48, S81-S84.	0.9	1
162	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 1025-1025.	0.8	1

#	Article	IF	Citations
163	Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis. , 2018, , .		1
164	Ode to a Past Emperor. Journal of Clinical Oncology, 2010, 28, 2938-2940.	0.8	0
165	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	0.9	0
166	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. Current Breast Cancer Reports, 2011, 3, 24-33.	0.5	0
167	Circulating Tumour Cells as Liquid Biopsy in Breast Cancerâ€"Advancing from Prognostic to Predictive Potential. Current Breast Cancer Reports, 2015, 7, 53-58.	0.5	0
168	Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes. Breast, 2016, 27, 189.	0.9	0
169	In Reply to Belkacemi and Tsoutsou. International Journal of Radiation Oncology Biology Physics, 2018, 102, 467-468.	0.4	0
170	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. Breast Journal, 2019, 25, 1225-1229.	0.4	0
171	Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 640-640.	0.8	0
172	A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).. Journal of Clinical Oncology, 2014, 32, 9546-9546.	0.8	0
173	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. Journal of Clinical Oncology, 2014, 32, 630-630.	0.8	0
174	Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. , 2015, , .		0
175	Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases.. Journal of Clinical Oncology, 2015, 33, 568-568.	0.8	0
176	Abstract 371: Longitudinal genetic characterization of circulating tumor cells in metastatic breast cancer patients. , 2015, , .		0
177	Serum metabolomics as biomarkers to differentiate early from metastatic disease and predict relapse in elderly colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2016, 34, 10042-10042.	0.8	0
178	Abstract CT010: Efficacy results based onPIK3CAstatus in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor. , 2017, , .		0
179	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	0.8	0
180	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. Journal of Clinical Oncology, 2019, 37, 538-538.	0.8	0

#	Article	IF	Citations
181	Abstract 2471: Pan-cancer catalog of Differentially Methylated Regions by Rocker-meth, a new computational method. , 2019, , .		0
182	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		0
183	Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , .		0